Article citationsMore>>
Li, Z., Graf, N., Herrmann, K., Jünger, A., Aichler, M., Feuchtinger, A., Baumgart, A., Walch, A., Peschel, C., Schwaiger, M., Buck, A., Keller, U. and Dechow, T. (2012) FLT-PET Is Superior to FDG-PET for Very Early Response Prediction in NPM-ALK-Positive Lymphoma Treated with Targeted Therapy. Cancer Research, 72, 5014-5024.
http://dx.doi.org/10.1158/0008-5472.CAN-12-0635
has been cited by the following article:
-
TITLE:
Preclinical Evaluation of CD40-Directed Immunotherapy in B-Cell Lymphoma Using [18F]Fluorothymidine-PET
AUTHORS:
Nicolas Graf, Zhoulei Li, Ken Herrmann, Michaela Aichler, Jolanta Slawska, Axel Walch, Christian Peschel, Markus Schwaiger, Andreas K. Buck, Tobias Dechow, Ulrich Keller
KEYWORDS:
CD40 Antibody, FLT-PET, Lymphoma, Therapy Monitoring
JOURNAL NAME:
Advances in Molecular Imaging,
Vol.5 No.2,
April
9,
2015
ABSTRACT: Background: Inhibition of the lymphoma surface antigen CD40 by the
antagonistic CD40 antibody NVP-HCD122 (HCD122) demonstrates activity in various
lymphoma subtypes. In this preclinical in
vivo study we examined the suitability of positron emission tomography
(PET) using the thymidine analogue 3’-deoxy-3’-[18F]fluorothymidine
(FLT) for early response assessment upon HCD122 treatment in diffuse large B
cell lymphoma (DLBCL). Methods: Immunodeficient mice bearing human DLBCL
xenografts (SU-DHL-4) received weekly intraperitoneal injections of HCD122.
Tumor growth was followed up until Day 14. Molecular imaging with FLT-PET was
performed before (Day 0) and after start of therapy (Day 2 and Day 7). On Day 14
lymphoma xenografts were explanted for immunohistochemical analysis to correlate
PET findings with CD40 surface expression on tumor tissue. Results: Treatment
with HCD122 significantly delayed tumor growth resulting in a tumor growth
inhibition of 45% on Day 14. Significant reduction of tumor-to-background ratio
(TBR) of FLT-PET was seen in treated animals on Day 7 and preceded change of
tumor volume, thus predicting therapy response to HCD122. Immunohistochemical
analysis of xenografts revealed significantly higher CD40 expression on treated
than on untreated tissue. Moreover, we found a significant correlation between
CD40 expression and FLT-PET response for xenograft tumor treated with HCD122. Conclusions:
Treatment of DLBCL with the antagonistic CD40 antibody HCD122 can be monitored
with FLT-PET as early as seven days after commencement of therapy and seems to
increase CD40 expression on tumor tissue.
Related Articles:
-
Esther Jimenez-Jimenez, Irene Ortiz, Neus Aymar, Raquel Roncero, Pedro Mateos, Marta Gimenez, Jose Pardo, Sebastià Sabater
-
Osmair Vital de Oliveira, Arlan da Silva Gonçalves
-
Ryusuke Murakami, Yoshimitsu Fukushima, Hitomi Tani, Kotomi Iwata, Shinichiro Kumita, Maki Nakai, Tomoko Kurita, Keiko Yanagihara, Hiroyuki Takei, Miyuki Matsubara
-
Peter E. Blase, Pieternel C. M. Pasker-de Jong, Anton Hagenbeek, Rob Fijnheer, Marie J. de Haas, John M. H. de Klerk
-
Xinmeng Wang, Jinzhi Lu, Cunjian Yi